Invention Grant
![5-[3-[piperzin-1-yl]-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS 4 and 5 inhibitors for treating E.G. osteoarthritis](/docs/US/2020-02-04/US10550100B2/abs.jpg.600x600.jpg)
- Patent Title: 5-[3-[piperzin-1-yl]-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS 4 and 5 inhibitors for treating E.G. osteoarthritis
-
Application No.: US16308380Application Date: 2017-06-01
-
Publication No.: US10550100B2Publication Date: 2020-02-04
- Inventor: Frédéric Gilbert Labéguère , Rama Heng , Frédéric André De Ceuninck , Luke Jonathan Alvey , David Amantini , Franck Laurent Brebion , Pierre Marc Marie Joseph Deprez , Romain Luc Marie Gosmini , Hélène Marie Jary , Christophe Peixoto , Iuliana Ecaterina Pop-Botez , Marie Laurence Claire Varin
- Applicant: GALAPAGOS NV , LES LABORATOIRES SERVIER
- Applicant Address: BE Mechelen
- Assignee: GALAPAGOS NV
- Current Assignee: GALAPAGOS NV
- Current Assignee Address: BE Mechelen
- Agency: Arent Fox LLP
- Priority: GB1610056.2 20160609
- International Application: PCT/EP2017/063272 WO 20170601
- International Announcement: WO2017/211667 WO 20171214
- Main IPC: C07D401/12
- IPC: C07D401/12 ; C07D401/14 ; A61P19/02 ; C07D409/14
![5-[3-[piperzin-1-yl]-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS 4 and 5 inhibitors for treating E.G. osteoarthritis](/abs-image/US/2020/02/04/US10550100B2/abs.jpg.150x150.jpg)
Abstract:
The present invention discloses compounds according to Formula I: Wherein R1, R2, R3a, R3b, R6, Cy, and the subscript n are as defined herein.The present invention relates to compounds inhibiting ADAMTS, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of inflammatory diseases, and/or diseases involving degradation of cartilage and/or disruption of cartilage homeostasis by administering the compound of the invention.
Public/Granted literature
Information query
